Erlotinib and concurrent chemoradiation in pretreated NSCLC patients: Radiobiological basis and clinical results

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Ramella, Sara ^a   Alberti, Antonio Maria ^b   Cammilluzzi, Eugenio ^b   Fiore, Michele ^a   Ippolito, Edy ^a   Greco, Carlo ^a   De Quarto, Angelo Luca ^b   Ramponi, Sara ^b   Apolone, Giovanni ^c   Trodella, Lucio ^a   Cesario, Alfredo ^d,e   D'Angelillo, Rolando Maria ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SANDRO PERTINI HOSPITAL   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; PEMETREXED; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; ESOPHAGITIS; EXPLORATORY RESEARCH; FEASIBILITY STUDY; FEMALE; GENE MUTATION; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHOTOPHOBIA; PRIMARY TUMOR; PROSPECTIVE STUDY; RADIATION PNEUMONIA; RADIOBIOLOGY; RASH; RETROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; STAPHYLOCOCCUS EPIDERMIDIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MIDDLE AGED; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY; LUNG TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84883160772     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/403869     Document Type: Article

References (14)

1. Blackhall F., Ranson M., Thatcher N., Where next for gefitinib in patients with lung cancer? The Lancet Oncology 2006 7 6 499 507 2-s2.0-33646888233 10.1016/S1470-2045(06)70725-2
2. Shepherd F. A., Pereira J. R., Ciuleanu T., Eng H. T., Hirsh V., Thongprasert S., Campos D., Maoleekoonpiroj S., Smylie M., Martins R., Van Kooten M., Dediu M., Findlay B., Tu D., Johnston D., Bezjak A., Clark G., Santabárbara P., Seymour L., Erlotinib in previously treated non-small-cell lung cancer. The New England Journal of Medicine 2005 353 2 123 132 2-s2.0-22044445517 10.1056/NEJMoa050753
3. Aupérin A., Le Péchoux C., Rolland E., Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. Journal of Clinical Oncology 2010 28 2181 2190
4. Tanaka T., Munshi A., Brooks C., Liu J., Hobbs M. L., Meyn R. E., Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clinical Cancer Research 2008 14 4 1266 1273 2-s2.0-39749129748 10.1158/1078-0432.CCR-07-1606
5. Baumann M., Krause M., Dikomey E., Dittmann K., Dörr W., Kasten-Pisula U., Rodemann H. P., EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiotherapy and Oncology 2007 83 3 238 248 2-s2.0-34250345258 10.1016/j.radonc.2007.04.006
6. Ang K. K., Berkey B. A., Tu X., Zhang H.-Z., Katz R., Hammond E. H., Fu K. K., Milas L., Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Research 2002 62 24 7350 7356 2-s2.0-0037115674
7. Schmidt-Ullrich R. K., Mikkelsen R. B., Dent P., Todd D. G., Valerie K., Kavanagh B. D., Contessa J. N., Rorrer W. K., Chen P. B., Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 1997 15 10 1191 1197 2-s2.0-0030772168
8. Chinnaiyan P., Huang S., Vallabhaneni G., Armstrong E., Varambally S., Tomlins S. A., Chinnaiyan A. M., Harari P. M., Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Research 2005 65 8 3328 3335 2-s2.0-17144371349
9. Ohnishi T., Taki T., Hiraga S., Arita N., Morita T., In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochemical and Biophysical Research Communications 1998 245 2 319 324 2-s2.0-0032540152 10.1006/bbrc.1998.8440
10. Choong N. W., Mauer A. M., Haraf D. J., Lester E., Hoffman P. C., Kozloff M., Lin S., Dancey J. E., Szeto L., Grushko T., Olopade O. I., Salgia R., Vokes E. E., Phase i trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. Journal of Thoracic Oncology 2008 3 9 1003 1011 2-s2.0-58149132003 10.1097/JTO.0b013e31818396a4
11. Center B., Petty W. J., Ayala D., Hinson W. H., Lovato J., Capellari J., Oaks T., Miller A. A., Blackstock A. W., A phase i study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. Journal of Thoracic Oncology 2010 5 1 69 74 2-s2.0-76149123903 10.1097/JTO.0b013e3181c59a0e
12. Wang J., Xia T.-Y., Wang Y.-J., Li H.-Q., Li P., Wang J.-D., Chang D.-S., Liu L.-Y., Di Y.-P., Wang X., Wu W.-Z., Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer. International Journal of Radiation Oncology Biology Physics 2011 81 3 e59 e65 2-s2.0-80053580476 10.1016/j.ijrobp.2010.12.035
13. Ramella S., Trodella L., Mineo T. C., Pompeo E., Gambacorta M. A., Cellini F., Ciresa M., Fiore M., Greco C., Gaudino D., Stimato G., Piermattei A., Cesario A., D'Angelillo R. M., Beams arrangement in non-small cell lung cancer (NSCLC) according to PTV and dosimetric parameters predictive of pneumonitis. Medical Dosimetry 2010 35 3 169 178 2-s2.0-77955260213 10.1016/j.meddos.2009.05.003
14. Komaki R., Blumenschein G. R. Jr., Wistuba I. I., Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III NSCLC. Journal of Clinical Oncology 2011 29 supplement, abstract 7020